Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-31

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to see if an automated insulin management system ("study system") can safely be used at home to manage blood sugar. The study system includes (1) a CGM that measures glucose levels, (2) a computer program on a smartphone that determines how much insulin is needed and allows the study participant user to control the whole system, and (3) an insulin pump that delivers the insulin. The CGM will be from Dexcom. The pump will be from Roche. The CGM and pump are similar to the devices that are currently available for people to purchase and use. However, the smartphone device, the CGM sensor type used with it, and the overall study system can only be used for research at this time.

The study will be completed by about 24 individuals at 6 centers in the United States and Europe. This study has several phases and will take about 11-14 weeks to complete depending on whether the study participant is a CGM user or not.

At selected sites (based on subject eligibility and availability), approximately 10-20 subjects who exhibit safe and competent use of the system at home will be given the option to continue home use of the system in Day-and-Night Closed-Loop mode for up to 5 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study

NCT01591681

Type 1 Diabetes

COMPLETED PHASE2

Inpatient Evaluation of an Automated Closed-Loop Control-to-Range System

NCT01271023

Type 1 Diabetes

COMPLETED PHASE1

An Outpatient Pump Shutoff Pilot Feasibility and Safety Study

NCT01736930

Type 1 Diabetes

COMPLETED PHASE2

Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control

NCT02679287

Diabetes Mellitus, Type 1

COMPLETED NA

In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes

NCT05238142

Type 2 Diabetes Treated With Insulin

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study phases are as follows:

* Screening visit to see if you are eligible for the study and to determine how long you will need to use the study CGM (visit 1)
* Up to 3 weeks using the study CGM (depends on your current CGM use), followed by an office visit (visit 2)
* 2 weeks using the study insulin pump and study CGM together
* Full day visit in clinic or hotel for training using the system (visit 3)
* 1 week using the system without automated insulin delivery or suspension
* 2-day hotel or clinic visit for closed-loop training (visit 4),
* 16-19 days using the system in the evening and overnight only followed by an office visit (visit 5)
* 16-19 days using the system for the full 24 hours
* Final study clinic visit (visit 6)
* Option 5 month extension phase of day-and-night closed-loop home use

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Closed-Loop Control System

Use of an investigational control-to-range automated insulin management (artificial pancreas) system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes in the home environment.

Group Type EXPERIMENTAL

Closed-Loop Control System

Intervention Type DEVICE

This investigational device system included the following components:

* DiAs - a smart-phone medical platform;
* Dexcom G4 Platinum CGM system connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;
* Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;
* Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network
* Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class

Sensor-Augmented Pump (SAP)

Use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump

Group Type ACTIVE_COMPARATOR

Sensor-Augmented Pump (SAP)

Intervention Type DEVICE

This commercial device system included the following components:

* Dexcom G4 Platinum CGM system;
* Roche Accu-Chek insulin pump

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Closed-Loop Control System

This investigational device system included the following components:

* DiAs - a smart-phone medical platform;
* Dexcom G4 Platinum CGM system connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;
* Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;
* Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network
* Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class

Intervention Type DEVICE

Sensor-Augmented Pump (SAP)

This commercial device system included the following components:

* Dexcom G4 Platinum CGM system;
* Roche Accu-Chek insulin pump

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Diabetes Assistant (DiAs)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year and using insulin for at least 1 year and an insulin pump for at least 6 months.
2. Age \>=18 to \<70 years.
3. HbA1c \<10.0%; if HbA1c \<6.0% then total daily insulin must be \>=0.5 U/kg
4. For females, not currently known to be pregnant. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative urine pregnancy test will be required for all premenopausal women who are not surgically sterile. Subjects who become pregnant will be discontinued from the study.
5. Demonstration of proper mental status and cognition for the study.
6. Currently using insulin-to-carbohydrate ratio to calculate meal bolus sizes
7. Hypoglycemia awareness as demonstrated by a Clarke Hypoglycemia Awareness score of 2 or lower
8. Access to internet and cell phone service at home, and a computer for downloading device data.
9. Living with significant other or family member committed to participating in all training activities, knowledgeable at all times of the participant's location, and being present and available to provide assistance when system is being used at night.
10. Commitment to maintaining uninterrupted availability via cell phone and avoiding any overnight travel for the duration of each two-week period using the closed-loop system.
11. An understanding of and willingness to follow the protocol and sign the informed consent.

Exclusion Criteria

1. Admission for diabetic ketoacidosis in the 12 months prior to enrollment.
2. Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment.
3. History of a seizure disorder (except hypoglycemic seizure), unless written clearance is received from a neurologist.
4. Coronary artery disease or heart failure, unless written clearance is received from a cardiologist.
5. History of cardiac arrhythmia (except for benign premature atrial contractions and benign premature ventricular contractions which are permitted)
6. Cystic fibrosis.
7. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:

* Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian)
* Presence of a known adrenal disorder
* Abnormal liver function test results (Transaminase \>2 times the upper limit of normal); testing required for subjects taking medications known to affect liver function or with diseases known to affect liver function
* Abnormal renal function test results (calculated GFR \<60); testing required for subjects with diabetes duration of greater than 5 years post onset of puberty
* Active gastroparesis
* If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study
* Uncontrolled thyroid disease (TSH undetectable or \>10); testing required within three months prior to admission for subjects with a goiter, positive antibodies, or who are on thyroid hormone replacement, and within one year otherwise
* Abuse of alcohol or recreational drugs
* Infectious process not anticipated to resolve prior to study procedures (e.g. meningitis, pneumonia, osteomyelitis)

7\. A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol 8. Current use of the following drugs and supplements:

* Acetaminophen
* Any medication being taken to lower blood glucose, such as Pramlintide, Metformin, GLP-1 Analogs such as Liraglutide, and nutraceuticals intended to lower blood glucose
* Beta blockers
* Oral or injectable glucocorticoids
* Any other medication that the investigator believes is a contraindication to the subject's participation

Minimum Eligible Age

18 Years

Maximum Eligible Age

69 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No